In the pre-rituximab era, three cycles of CHOP plus RT became the standard of care after the phase III SWOG S8736 study showed improved PFS and OS compared with 8 cycles of CHOP alone in localized intermediate- and high-grade non-Hodgkin’s lymphoma [40]. This evidence concerns the gene DDIT3 and non-Hodgkin lymphoma.